These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 10399063)

  • 1. Chemokine receptor trafficking and viral replication.
    Pelchen-Matthews A; Signoret N; Klasse PJ; Fraile-Ramos A; Marsh M
    Immunol Rev; 1999 Apr; 168():33-49. PubMed ID: 10399063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocytic trafficking of chemokine receptors.
    Marchese A
    Curr Opin Cell Biol; 2014 Apr; 27():72-7. PubMed ID: 24680433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral chemokine receptors and chemokines in human cytomegalovirus trafficking and interaction with the immune system. CMV chemokine receptors.
    Beisser PS; Goh CS; Cohen FE; Michelson S
    Curr Top Microbiol Immunol; 2002; 269():203-34. PubMed ID: 12224510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.
    Scarlatti G; Tresoldi E; Björndal A; Fredriksson R; Colognesi C; Deng HK; Malnati MS; Plebani A; Siccardi AG; Littman DR; Fenyö EM; Lusso P
    Nat Med; 1997 Nov; 3(11):1259-65. PubMed ID: 9359702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemokine receptors intracellular trafficking.
    Borroni EM; Mantovani A; Locati M; Bonecchi R
    Pharmacol Ther; 2010 Jul; 127(1):1-8. PubMed ID: 20451553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Cytomegalovirus UL111A and US27 Gene Products Enhance the CXCL12/CXCR4 Signaling Axis via Distinct Mechanisms.
    Tu CC; Arnolds KL; O'Connor CM; Spencer JV
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How can human and simian immunodeficiency viruses utilize chemokine receptors as their coreceptors?
    Shimizu N; Gojobori T
    Gene; 2000 Dec; 259(1-2):199-205. PubMed ID: 11163977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TYMSTR, a putative chemokine receptor selectively expressed in activated T cells, exhibits HIV-1 coreceptor function.
    Loetscher M; Amara A; Oberlin E; Brass N; Legler D; Loetscher P; D'Apuzzo M; Meese E; Rousset D; Virelizier JL; Baggiolini M; Arenzana-Seisdedos F; Moser B
    Curr Biol; 1997 Sep; 7(9):652-60. PubMed ID: 9285716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous ligand bias by chemokines: implications at the front lines of infection and leukocyte trafficking.
    Zidar DA
    Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):120-31. PubMed ID: 21476969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II.
    Zhou N; Luo Z; Luo J; Hall JW; Huang Z
    Biochemistry; 2000 Apr; 39(13):3782-7. PubMed ID: 10736178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary isolated human brain microvascular endothelial cells express diverse HIV/SIV-associated chemokine coreceptors and DC-SIGN and L-SIGN.
    Mukhtar M; Harley S; Chen P; BouHamdan M; Patel C; Acheampong E; Pomerantz RJ
    Virology; 2002 May; 297(1):78-88. PubMed ID: 12083838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of human cytomegalovirus (HCMV) US27 on CXCR4 receptor internalization measured by fluorogen-activating protein (FAP) biosensors.
    Boeck JM; Spencer JV
    PLoS One; 2017; 12(2):e0172042. PubMed ID: 28207860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [AIDS; new developments. V. The role of chemokines and chemokine receptors during infection with HIV].
    Brinkman K; Koopmans PP
    Ned Tijdschr Geneeskd; 1998 Mar; 142(11):566-72. PubMed ID: 9623113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors.
    Choi WT; Tian S; Dong CZ; Kumar S; Liu D; Madani N; An J; Sodroski JG; Huang Z
    J Virol; 2005 Dec; 79(24):15398-404. PubMed ID: 16306611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feline immunodeficiency virus xenoinfection: the role of chemokine receptors and envelope diversity.
    Johnston JB; Power C
    J Virol; 2002 Apr; 76(8):3626-36. PubMed ID: 11907202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonproductive human immunodeficiency virus type 1 infection of human fetal astrocytes: independence from CD4 and major chemokine receptors.
    Sabri F; Tresoldi E; Di Stefano M; Polo S; Monaco MC; Verani A; Fiore JR; Lusso P; Major E; Chiodi F; Scarlatti G
    Virology; 1999 Nov; 264(2):370-84. PubMed ID: 10562499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.
    Alkhatib G; Locati M; Kennedy PE; Murphy PM; Berger EA
    Virology; 1997 Aug; 234(2):340-8. PubMed ID: 9268166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus-encoded chemokine receptors--putative novel antiviral drug targets.
    Rosenkilde MM
    Neuropharmacology; 2005 Jan; 48(1):1-13. PubMed ID: 15617722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokine expression during the development and resolution of a pulmonary leukocyte response to influenza A virus infection in mice.
    Wareing MD; Lyon AB; Lu B; Gerard C; Sarawar SR
    J Leukoc Biol; 2004 Oct; 76(4):886-95. PubMed ID: 15240757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SMM-chemokines: a class of unnatural synthetic molecules as chemical probes of chemokine receptor biology and leads for therapeutic development.
    Kumar S; Choi WT; Dong CZ; Madani N; Tian S; Liu D; Wang Y; Pesavento J; Wang J; Fan X; Yuan J; Fritzsche WR; An J; Sodroski JG; Richman DD; Huang Z
    Chem Biol; 2006 Jan; 13(1):69-79. PubMed ID: 16426973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.